GlassScriptPhysician profile
Alan Zaccaria
NPI 1154316123
$1,978.37
in general payments reported to CMS, 2019-2025
11 companies · $539 in 2025
The $539 reported for 2025 was more than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $165 · 2021: $211 · 2022: $112 · 2023: $258 · 2024: $425 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,221.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $421.76 | 2024-2025 | |
| Allergan, INC. | $375.19 | 2019-2022 | |
| Polynovo North America LLC | $171.85 | 2023 | |
| Motiva USA, LLC | $169.62 | 2025 | |
| Sientra, INC. | $165.00 | 2020 | |
| Acera Surgical, INC. | $160.85 | 2024 | Restrata Wound Matrix |
| Convatec INC. | $118.70 | 2024 | |
| Zimmer Biomet Holdings, INC. | $116.32 | 2019 | |
| Mentor Worldwide LLC | $100.00 | 2019 | |
| Revance Therapeutics, INC. | $93.28 | 2025 | Daxxify |
| Tela Bio, INC. | $85.80 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Zaccaria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.